Clinical Trial Update: Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Solifenacin succinate 5 mg or 10 mg once daily for urgency symptoms in overactive bladder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Vesicare (solifenacin succinate)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Urinary Bladder, Overactive | Phase 3 | Status: COMPLETED